Matt Miksic
Stock Analyst at Barclays
(1.99)
# 1373
Out of 5,266 analysts
254
Total ratings
61.39%
Success rate
11.32%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Baxter Intl | Reinstates: Overweight | 39 | 33.56 | 16.21% | 16 | Feb 20, 2025 | |
Edwards Lifesciences | Maintains: Overweight | 88 90 | 73.88 | 21.82% | 23 | Feb 13, 2025 | |
Zimmer Biomet Holdin... | Maintains: Underweight | 118 112 | 104.67 | 7% | 7 | Feb 10, 2025 | |
Stryker | Maintains: Overweight | 418 443 | 384.61 | 15.18% | 21 | Feb 10, 2025 | |
Boston Scientific | Maintains: Overweight | 111 118 | 104.91 | 12.48% | 13 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 29 | 18.9 | 53.44% | 12 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 159 166 | 162.21 | 2.34% | 11 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 149 158 | 135.05 | 16.99% | 25 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 21 | 10.61 | 97.93% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 8.3 | 165.06% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 16 | 5.01 | 219.36% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 109 | 90.17 | 20.88% | 15 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 234 | 280.1 | -16.46% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 60 | 31.43 | 90.9% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 85 93 | 79.94 | 16.34% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 138 113 | 88.79 | 27.27% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 490 510 | 596.99 | -14.57% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 16 | 13.16 | 21.58% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 61 | 47.59 | 28.18% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 17 18 | 15.72 | 14.5% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 90.47 | 6.11% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 76.97 | 29.92% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 188.99 | 121.18% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 13.53 | 106.95% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 18.79 | 256.57% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 14.15 | 3292.23% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 21.61 | 302.59% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 3.29 | 659.88% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 7.93 | 13.49% | 1 | Dec 12, 2016 |